Global Blood Therapeutics (NASDAQ: GBT)
Some price data may be temporarily unavailable.
Global Blood Therapeutics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Global Blood Therapeutics Company Info
GLOBAL BLOOD THERAPEUTICS INC COM USD0.001
News & Analysis
Why Global Blood Therapeutics Stock Was Trouncing the Market Today
The blood-disorder specialist sells itself in a deal with an enterprise value of around $5.4 billion.
Why Global Blood Therapeutics Stock Is Vaulting Higher Today
Pfizer emerges as the lead suitor for the rare-disease company.
Why Global Blood Therapeutics Stock Is Soaring Today
A buyout rumor is powering the biotech's shares higher.
Why Global Blood Therapeutics Trended Upward Today
It started enrolling patients in a promising new clinical trial.
Why Global Blood Therapeutics Stock Was Sickly Today
The bears pounced on the company despite a first-quarter bottom-line beat.
Why Global Blood Therapeutics Sank by 14% Today
Investors aren't impressed with the company's latest financing move.
Why Shares of Global Blood Therapeutics Are Soaring Today
The biotech company has only one drug, Oxbryta, on the market, to treat sickle cell disease. Its shares were up Monday after falling on Friday.
Why Global Blood Therapeutics Is Rallying Today
This heavily shorted biotech finally had some good news.
Valuation
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.